Cannovex BV provides pharmacies with the highest purity cannabidiol (CBD) as Active Pharmaceutical Ingredient.
CANNOVEX receives EUR 0.5 million grant for development of nanofibrous films for transmucosal uptake of cannabinoids.
Diepenbeek, Belgium, 14 October 2020 – Cannovex BV (the ‘Company’ or ‘Cannovex), a developer of cannabinoid-based medicines today announces that it has been awarded a EUR 0.5 million development grant…Read More
Cannovex envisages to set up clinical studies to provide Proofs of Concept, to be followed by end-stage clinical trials in partnership with pharmaceutical companies to evidence the safety and efficacy of the selected cannabinoid drug candidates and apply for market authorisation with EMA and FDA thus paving the path to the market.
Since its inception in 2016, Cannovex has merited the position as the designated conversation partner, sounding board and source of information on cannabinoid medicines. Following a quick scan of medical literature on the subject, the founders of Cannovex decided to create a venture to develop cannabinoid-based medicines.
Industry concepts of cannabinoid-BASED medicines
Medicinal cannabis, cannabinoid-based medicine,… what’s in a name?
This infographic provides an overview of the various concepts.
Cannovex is focusing on concept 4.0 – i.e. the development of cannabinoid-based medicines.
Cannovex has entered into partnerships with universities and institutions for scientific research and business development, both in Belgium as in The Netherlands. Cannovex is open for partnerships to accomplish its mission to improve patients’ lives by developing cannabinoid-based medicines.
© 2020 – Cannovex BV – All rights reserved
Tel: +32 11 28 69 00